Skip to main content

Search Videos and More

Showing 37 - 48 of 162 results

Previous| 1... 3 | 4 | 5 ...14 |Next

How vigorous should we be in trying to lower LDL-C in patients who have statin intolerance? What is the role of combined—so-called “backbone”—statin treatment plus PCSK9 inhibitor therapy?

How vigorous should we be in trying to lower LDL-C in patients who have statin intolerance? What is the role of combined—so-called “backbone”—statin treatment plus PCSK9 inhibitor therapy?

From the specific vantage point of the interventional cardiologist, based on the results of the ODYSSEY Outcomes Trial, which patients who have undergone PCI do you believe are the best candidates for PCSK9 therapy?

From the specific vantage point of the interventional cardiologist, based on the results of the ODYSSEY Outcomes Trial, which patients who have undergone PCI do you believe are the best candidates for PCSK9 therapy?

Interventional cardiologists have a strong incentive to use PCSK9 inhibitors in many high-risk patients, but real world factors such as cost can present barriers to optimizing CV risk prevention. Can you discuss this and its relevance to the IC?

Interventional cardiologists have a strong incentive to use PCSK9 inhibitors in many high-risk patients, but real world factors such as cost can present barriers to optimizing CV risk prevention. Can you discuss this and its relevance to the IC?

How has our knowledge of the safety and efficacy of PCSCK9 inhibitors evolved, and how has the ODYSSEY Outcomes “treat-to-target” trial helped us translate these advances into the front lines of interventional cardiology practice?

How has our knowledge of the safety and efficacy of PCSCK9 inhibitors evolved, and how has the ODYSSEY Outcomes “treat-to-target” trial helped us translate these advances into the front lines of interventional cardiology practice?

What have we learned from the ODYSSEY Outcomes pharmacoeconomic analysis that you and Professor Deepak Bhatt reported at the AHA 2018 Meeting? And what are the implications for the clinician-cardiologist who is making the case to payors?

What have we learned from the ODYSSEY Outcomes pharmacoeconomic analysis that you and Professor Deepak Bhatt reported at the AHA 2018 Meeting? And what are the implications for the clinician-cardiologist who is making the case to payors?

From the perspective of a lipid medicine specialist, how do the results of the now-published ODYSSEY Outcomes Trial, and related trials, help you select patients for PCSK9-mediated LDL-C reduction? And what targets do you advocate?

From the perspective of a lipid medicine specialist, how do the results of the now-published ODYSSEY Outcomes Trial, and related trials, help you select patients for PCSK9-mediated LDL-C reduction? And what targets do you advocate?

Why is down-titration from a high-intensity statin dose potentially problematic, and what are the pragmatic implications as they relate to PCSK9 inhibitor use in patients who cannot achieve optimal CV reduction with statin therapy?

Why is down-titration from a high-intensity statin dose potentially problematic, and what are the pragmatic implications as they relate to PCSK9 inhibitor use in patients who cannot achieve optimal CV reduction with statin therapy?

Which patient subgroups that, based on the Odyssey Outcomes Trial, could benefit significantly from a PCSK9 inhibitor, in your observation, are not getting treatment consistently enough—i.e. are being “under-treated”—with these agents?

Which patient subgroups that, based on the Odyssey Outcomes Trial, could benefit significantly from a PCSK9 inhibitor, in your observation, are not getting treatment consistently enough—i.e. are being “under-treated”—with these agents?

Given what we know about the safety of PCSK9 inhibitors and the risk of recurrent events in patients who have experienced an ACS,

Given what we know about the safety of PCSK9 inhibitors and the risk of recurrent events in patients who have experienced an ACS,

What is the unmet need for residual CV risk reduction in post-ACS patients with T2D? In your role as a member of the LDL Guideline Group for AACE, what were the implications of treating diabetic patients with so-called “extreme risk”?”

What is the unmet need for residual CV risk reduction in post-ACS patients with T2D? In your role as a member of the LDL Guideline Group for AACE, what were the implications of treating diabetic patients with so-called “extreme risk”?”

Can you provide some specific examples of patients in your general cardiology practice in whom you have prescribed PCSK9 inhibitors and your rationale and the evidentiary basis for doing so? When does statin intolerance play a role?

Can you provide some specific examples of patients in your general cardiology practice in whom you have prescribed PCSK9 inhibitors and your rationale and the evidentiary basis for doing so? When does statin intolerance play a role?

If someone is more than 12 months out after an ACS event and currently has a stent, would you still consider them to be eligible for PCSK9 therapy to lower LDL-C and residual CV risk?

If someone is more than 12 months out after an ACS event and currently has a stent, would you still consider them to be eligible for PCSK9 therapy to lower LDL-C and residual CV risk?

Showing 37 - 48 of 162 results

Previous| 1... 3 | 4 | 5 ...14 |Next